



Mehra Golshan

Contact

Mehra Golshan

Publications (4)

Metzger-Filho O, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans W, Geyer C, Loibl S, Sikov W, Golshan M, Collier K, Asad S, Ansell P, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo H, Huober J, Stover D. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. *NPJ Breast Cancer* 2021; 7:142.

Filho O, Rugo H, Huober J, Golshan M, Sikov W, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Untch M, O'Shaughnessy J, Stover D, Asad S, Ansell P, Watson M, Loibl S, Geyer C, Bae J, Collier K, Cherian M, Symmans W. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrightTNess Phase 3 Randomized Clinical Trial. *JAMA Oncol* 2021; 7:603-608.

Golshan M, Sikov W, Geyer C, von Minckwitz G, Metzger-Filho O, Sullivan D, Maag D, Ansell P, Wolmark N, Rugo H, O'Shaughnessy J, Huober J, Loibl S, Wong S, Untch M. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrightTNess trial. *Eur J Surg Oncol* 2019; 46:223-228.

Loibl S, Liu X, Symmans W, Rastogi P, Metzger Filho O, Ponce Lorenzo J, McIntyre K, Wolmark N, Sullivan D, Maag D, von Minckwitz G, Golshan M, Huober J, McKee M, Rugo H, Sikov W, Untch M, O'Shaughnessy J, Geyer C. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrightTNess): a randomised, phase 3 trial. *Lancet Oncol* 2018; 19:497-509.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch